Effect of tocilizumab (TCZ) on clinical and laboratory measures of Still’s disease activity after 6 months of treatment and at the end of followup. Values are mean ± SD.
| Before TCZ | After 6 Months TCZ | End of Followup | |
|---|---|---|---|
| Tender joints, n | 11.6 ± 6.8 | 2 ± 1.8* | 1.4 ± 2.1* |
| Swollen joints, n | 8.6 ± 5.4 | 1.09 ± 1.6* | 0.7 ± 1.5* |
| Fever, n | 9 | 0* | 0* |
| Prednisone dosage, mg/d | 27.6 ± 26.3 | 4.9 ± 4* | 3.8 ± 4.9* |
| ESR, mm/h | 60 ± 28 | 3.9 ± 1.4* | 4.5 ± 1.9* |
| CRP, mg/dl | 11.6 ± 15 | 0.5 ± 0.1* | 0.5 ± 0.5* |
↵* Statistically significant, p < 0.05. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.